The US FDA and Health Canada have both announced that they are reviewing the cardiovascular (CV) safety of dronedarone [Multaq]

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1362, 2011-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

US FDA reviewing safety of orlistat

By  

Reactions Weekly, Vol. 1, Iss. 1267, 2009-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

The US FDA has made updates to the Revlimid [lenalidomide] label, similar to those announced recently by Health Canada.

By  

Reactions Weekly, Vol. 1, Iss. 1402, 2012-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

US FDA reviewing safety of ezetimibe/simvastatin

By  

Reactions Weekly, Vol. 1, Iss. 1217, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

US FDA reviewing safety of ezetimibe/simvastatin

By  

Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

FDA updates labelling for dronedarone with CV, death risk

By  

Reactions Weekly, Vol. 1, Iss. 1383, 2012-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite